Navigation Links
Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses
Date:10/22/2008

ned in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:

Joachim Fleing

Phone: +49-160-741-27-17

Fax: +49-2302-915-191

e-mail: fleing@sangui.de


'/>"/>
SOURCE Sangui Bio Tech International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangui Partnership Enters a New Phase:
2. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
3. Investors Acquire Share in Sangui BioTech GmbH
4. Sangui BioTech International, Inc. Files Remaining Reports
5. Sangui Bio Tech International Inc. Shareholders Meeting Delayed to Include FY 2008 Report
6. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
9. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
10. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
11. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , ... August 26, 2015 , ... ... announces today that a second US laboratory is to open in Manhattan, Kansas ... the continued partnership and long-term growth of research and development through collaboration with ...
(Date:8/26/2015)...  Platform therapeutic company Symic Biomedical, Inc. ("Symic") ... Phase II SBIR grant from the National Institutes ... agent to reduce arteriovenous fistula (AVF) failures, a ... disease (ESRD) patients undergoing hemodialysis. The two-year project, ... Digestive and Kidney Diseases (NIDDK), will allow Symic ...
(Date:8/26/2015)... , August 26, 2015 ... factors fueling the optimism in biotech,s forecast is ... and life sciences advancements.  Active biotechnology & healthcare ... BioSciences, Inc. (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: ... ), Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, ... Knapp, Wis. The company has added a AS16 Sharples centrifuge to harvest products ... during bacterial or fungal fermentation process development. , The new centrifuge greatly ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New centrifuge and fermentor expand product development capacity at Vets Plus 2
... cells is vital for our bodies to function. Part ... called neurotransmitters. The vesicle fuses with the nerve cell ... the next nerve cell. It is crucial that new ... continuously to take place. If parts of this communication ...
... Cleveland Clinic initiates dosing in ASSERT Trial , TSX ... Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today ... Phase 2 clinical trial lead by Cleveland Clinic. This ... for the treatment of atherosclerosis, in patients with stable ...
... , SHANGHAI, Dec. 22 ... in China, announced today that,the company has received 2009 Deloitte ... year to win this award. The news was,announced at a ... Kong. , The Deloitte Technology Fast ...
Cached Biology Technology:New insight in nerve cell communication 2Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial 2Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial 3Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial 4
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, Inc., ... gene function analysis and biomarker discovery, announced the ... Knockout Library targeting all human protein coding genes. ... "knock out" a gene,s function. Cellecta,s new Human ... throughput screening tool so that researchers can investigate ...
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... at the University of Toronto, The Hospital for Sick ... British Columbia have identified a new treatment target for ... estimated 10% of common colds. The virus, called human ... reason for hospitalization of infants and children under two ...
... August 16th issue of Developmental Cell , researchers at ... that new blood vessels form in the right place and ... long time that blood vessels branch to give rise to ... this branching occurs with a reproducible pattern. However, the mechanisms ...
... A study out of York University has some refreshing ... Published today in the journal Applied Physiology, Nutrition and ... otherwise healthy live just as long as their slim counterparts, ... "Our findings challenge the idea that all obese individuals ...
Cached Biology News:Researchers map pathway of infection for a common, potentially life-threatening respiratory virus 2Fat and healthy? York U study finds slim isn't always superior 2
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Request Info...
Recombinant Mouse Wnt-3a...
... There are at least 20 structurally ... of the TGF-beta superfamily. BMPs were originally ... bone formation. They are also involved in ... organs. BMPs regulate the growth, differentiation, chemotaxis ...
Biology Products: